Compare RR & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | DNA |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 690.2M | 607.1M |
| IPO Year | 2023 | N/A |
| Metric | RR | DNA |
|---|---|---|
| Price | $5.45 | $9.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 32.2M | 884.9K |
| Earning Date | 01-20-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,045,000.00 | ★ $180,606,000.00 |
| Revenue This Year | $147.00 | N/A |
| Revenue Next Year | $37.21 | $3.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.37 | $5.00 |
| 52 Week High | $7.43 | $17.58 |
| Indicator | RR | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 68.03 | 53.36 |
| Support Level | $3.81 | $8.82 |
| Resistance Level | $4.85 | $11.10 |
| Average True Range (ATR) | 0.52 | 0.62 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 93.18 | 40.35 |
Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.